CSIMarket
 
Alpine Immune Sciences Inc   (ALPN)
Other Ticker:  
 
 
Price: $36.3800 $0.49 1.365%
Day's High: $37.37 Week Perf: 2.83 %
Day's Low: $ 35.56 30 Day Perf: 24.89 %
Volume (M): 4,021 52 Wk High: $ 39.27
Volume (M$): $ 146,295 52 Wk Avg: $14.95
Open: $35.92 52 Wk Low: $6.40



 Market Capitalization (Millions $) 1,791
 Shares Outstanding (Millions) 49
 Employees 36
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -108
 Capital Exp. (TTM) (Millions $) 0

Alpine Immune Sciences Inc
Alpine Immune Sciences Inc is a clinical-stage biotechnology company that develops immunotherapies to treat cancer, autoimmune disorders, and other diseases. The company's proprietary technology platform, called Transmembrane Immunomodulatory Protein (TIP) technology, allows the modification and enhancement of various immune system proteins for a more targeted and effective immune response.

The company's pipeline includes several product candidates in various stages of development. ALPN-101, the company's lead product candidate, is a dual ICOS/CD28 antagonist designed to treat autoimmune and inflammatory diseases. The drug is currently in Phase 2 clinical trials for patients with systemic lupus erythematosus (SLE), and additional trials are planned for rheumatoid arthritis, psoriasis, and other indications.

Another product candidate, ALPN-202, is a bi-functional fusion protein that targets both PD-L1 and CTLA-4 in the tumor microenvironment. This product candidate is being developed for the treatment of solid tumors and is currently in preclinical development.

Alpine Immune Sciences also has collaborations with several companies, including AbbVie, Bristol Myers Squibb, and Kite, a Gilead Company, to develop innovative immunotherapies.

The company was founded in 2015 and is headquartered in Seattle, Washington. It became a public company in 2017 and is traded on the NASDAQ under the ticker symbol ALPN. It has a market capitalization of approximately $172 million as of June 202 The company has a dedicated team of experienced professionals, including scientists and industry veterans, who are committed to developing innovative immunotherapies to improve the lives of patients.


   Company Address: 188 East Blaine Street, Suite 200 Seattle 98102 WA
   Company Phone Number: 788-4545   Stock Exchange / Ticker: NASDAQ ALPN
   ALPN is expected to report next financial results on March 22, 2024.


Customers Net Income grew by ALPN's Customers Net Profit Margin grew to

16.22 %

-115.9 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMAT   -2.05%    
APH   -0.91%    
GLW   -1.7%    
KLAC   -1.1%    
LRCX   -2.69%    
TEL   -0.38%    
• View Complete Report
   



Business Update

Alpine Immune Sciences Strengthens Partnership with AbbVie and Achieves Impressive Revenue Growth Amidst Pandemic Challenges

Published Thu, Dec 21 2023 9:15 PM UTC

Alpine Immune Sciences Updates License Agreement with AbbVie and Demonstrates Revenue GrowthSeattle-based immunotherapy company, Alpine Immune Sciences, has announced an amendment to its option and license agreement with AbbVie, a global biopharmaceutical company. The agreement focuses on the development of acazicolcept, an innovative treatment for autoimmune and inflammator...

Product Service News

Alpine Immune Sciences' Breakthrough Therapy for Systemic Lupus Erythematosus Shines at ACR Convergence 2023, Fueling Remarkable Revenue Growth

Published Wed, Nov 15 2023 2:00 PM UTC

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus and Reports Strong Revenue Growth
Alpine Immune Sciences, a renowned clinical-stage immunotherapy company specializing in innovative treatments for autoimmune and inflammatory diseases, recently presented new translational data for povetacicept (ALPN-303) in systemic lu...

Product Service News

Alpine Immune Sciences Showcases Promising Translational Data for Acazicolcept in Systemic Lupus Erythematosus at ACR Convergence 2023

Published Mon, Nov 13 2023 2:00 PM UTC



Alpine Immune Sciences Inc, a renowned clinical-stage immunotherapy company, recently presented groundbreaking translational data for its innovative treatment, acazicolcept (ALPN-101), in the field of systemic lupus erythematosus (SLE). The announcement was made at the prestigious American College of Rheumatology Convergence 2023, which took place from November 10t...

Product Service News

Alpine Immune Sciences Presents Promising Clinical Data on Povetacicept for Autoimmune Glomerulonephritis at ASN Kidney Week 2023

Published Thu, Nov 2 2023 1:00 PM UTC



Seattle-based biopharmaceutical company, Alpine Immune Sciences, is making waves in the field of immunotherapy with their groundbreaking treatment, povetacicept. The company recently presented the first set of clinical data on the efficacy of this novel drug in treating autoimmune glomerulonephritis, during a late-breaking poster session at the prestigious American...

Alpine Immune Sciences Inc

Alpine Immune Sciences Inc. Reports Impressive Revenue Increase of 62%, Slashes Losses in Q2 2023

Alpine Immune Sciences Inc., a company in the Major Pharmaceutical Preparations sector, recently reported an impressive revenue increase in its Jun 30 2023 report. The report showcased a revenue elevation of 62.377% to $8.59 million, which has helped the company in cutting its losses to $-0.27 per share, a significant improvement from the loss of $-0.60 per share in the same quarter the previous year.
This revenue improvement is seen as a new revelation for many, especially considering the fact that the Major Pharmaceutical Preparations sector has been experiencing a contraction of -9.33% in its top-line. However, it is essential to analyze the market conditions and other factors before assuming that this positive trend will continue for Alpine Immune Sciences Inc.
Despite the revenue improvement, there are concerns regarding the company's Q1 performance. The revenue for this quarter deteriorated by -8.459% from $9.39 million, although the earnings per share (EPS) did show an improvement from $-0.28 per share. This decline in revenue raises questions about the sustainability of the positive trend witnessed in the most recent report.






 

Alpine Immune Sciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com